Sign In
Last checked at 
19 May 2026 09:56
PDMR Dealing
Oxford, UK - 19 May 2026: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Kathleen Miller has exercised 4,486 Restricted Share Units ("RSU") options granted under the 2024 Long Term Incentive Plan ("2024 LTIP Plan") at an exercise price of £nil on 18 May 2026 and disposed of 1,578 ordinary shares at an average price of £6.091 per share on 18 May 2026.
The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.
1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
b) | Name of natural person | Kathleen Miller | ||||
c) | Legal person | |||||
2. | Reason for the notification | |||||
a) | Position/status | Head of Human Resources (and acting Interim Site Head, Bedford Operations) | ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Full name of the entity | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Date of the transaction | 18-May-2026 | ||||
b) | Description of the financial instrument | Share
| ||||
c) | Identification code | ISIN: GB00BDFBVT43 | ||||
d) | Nature of the transaction | Exercise of 4,486 RSUs under 2024 LTIP Plan | ||||
e) | Place of the transaction | Outside the trading venue | ||||
f) | Currency | GBP - British pound | ||||
g) | Price(s) and volumes(s)
|
| ||||
h) | Aggregated information - Aggregate volume - Price - Aggregated total |
4,486 £0.00 £0.00 | ||||
1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
b) | Name of natural person | Kathleen Miller | ||||
c) | Legal person | |||||
2. | Reason for the notification | |||||
a) | Position/status | Head of Human Resources (and acting Interim Site Head, Bedford Operations) | ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Full name of the entity | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Date of the transaction | 18-May-2026 | ||||
b) | Description of the financial instrument | Share
| ||||
c) | Identification code | ISIN: GB00BDFBVT43 | ||||
d) | Nature of the transaction | Sale of 1,578 ordinary shares | ||||
e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
f) | Currency | GBP - British pound | ||||
g) | Price(s) and volumes(s)
|
| ||||
h) | Aggregated information - Aggregate volume - Price - Aggregated total |
1,578 £6.091 £9,611.60 | ||||
-Ends-
Enquiries:
OXB:
Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com
Mary-Jane Elliott / Sarah Elton-Farr / Angela Gray
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
Follow the stocks
